Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research ...

Diagnosed with mild cognitive impairment (MCI) in 2018, Mr Almond, from Esher, took part in two 18-month trials for donanemab ...

Donanemab, the most effective treatment yet for the disease, has been banned on the health service despite regulators ...

Expanding public education, increasing access and quality of care, supporting family caregivers and increasing training for ...

NICE has said the Alzheimer's disease drug is too expensive to be available on the NHS, but researchers are now hoping to ...

The UK’s National Institute of Health and Care Excellence (NICE) said the drug provided only a small benefit to patients.

UK MHRA grants marketing approval to Lilly's Kisunla to treat mild cognitive impairment and mild dementia due to Alzheimer's disease: Indianapolis Thursday, October 24, 2024, 09:0 ...

If I were a statistician tucked away in an NHS backroom, I might well curse the day the health service was founded. There, on ...

Health spending watchdog said costs could not justify benefits after treatment slowed cognitive decline by around four to ...

The Alzheimer's Society Cymru has responded to the approval of a new Alzheimer's treatment. The Medicines and Healthcare products Regulatory Agency (MHRA) announced on Wednesday, October 23, that it ...